Please assess the completion status of the following clinical trial:

Trial Title: A Safety Study of Liposomal Cyclosporine A to Treat Bronchiolitis After Hematopoietic Transplant (BOSTON-4)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Age \>/= 18 years~2. Patient must have a history of allogeneic HSCT, regardless of source of stem cell or donor or indication for allogeneic HSCT~3. Documented diagnosis of chronic Graft versus Host Disease (cGvHD) in any organ other than the lung. If BOS is the only manifestation of cGvHD, lung biopsy must have been performed before entering the trial to confirm BOS diagnosis.~4. Confirmed diagnosis of BOS Score 1 \[Jagasia et al. 2015\] within \> 6 months and \< 3 years after allo-HSCT:~   FEV1/FVC \< 0.7 at Screening Visit AND Post-bronchodilator FEV1 \>/= 60 and ≤ 79% predicted at Screening Visit AND~  * 10% decline of FEV1 % predicted within 24 months prior to Screening Visit AND Absence of acute infection in the respiratory tract.~5. Patient must be capable of understanding the purposes and risks of the study, has given written informed consent, and agrees to comply with the study requirements.~6. Patient is capable of aerosol inhalation.~7. Women of childbearing potential must have a negative serum or urine pregnancy test at screening and at randomization visit.~Exclusion Criteria:~1. Active bacterial, viral (as confirmed by multiplex PCR) or fungal infection not successfully resolved at least 4 weeks prior to the Screening Visit.~2. Chronic renal dysfunction with serum creatinine \>/= 2.5 mg/dL or need for renal dialysis.~3. Chronic hepatic dysfunction with serum total bilirubin \> 5x upper limit of normal (ULN), transaminases \> 5x ULN, or alkaline phosphatase \> 5x ULN.~4. Evidence of relapse of the primary malignancy which warranted allogeneic bone marrow transplant.~5. Use of azithromycin within 4 weeks prior to Randomization (Visit 1).~6. Use of zafirlukast during the study period.~7. Chronic oxygen use or use of non-invasive ventilation.~8. Active smokers (i.e. any kind of inhaled nicotine consumption).~9. Pregnant women or women who are unwilling to use appropriate birth control to avoid pregnancy over the course of the clinical trial.~10. Women who are currently breastfeeding.~11. Known hypersensitivity to L-CsA or to cyclosporine A.~12. Patients who do not tolerate administration of inhaled bronchodilators (e.g., salbutamol).~13. Patients with life-expectancy of less than 6 months.~14. Treatments with other Investigational Medicinal Products (IMPs) or previous therapies within four weeks or five times half-life of the drug, whichever is longer prior to screening and during the study. Participation in registries, considering the before, is allowed.~15. Psychiatric disorders or altered mental status precluding understanding of the informed consent process and/or completion of the necessary procedures.~16. Any co-existing medical condition that in the Investigator's judgment will substantially increase the risk associated with the patient's participation in the clinical trial.~17. Pre-scheduled hospitalizations, surgeries or interventions planned to be performed after obtaining Informed Consent for this study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- L-CsA 10 mg plus Standard of Care (Type: EXPERIMENTAL): Liposomal Cyclosporine A 10 mg (10 mg/2.5 mL) bid, once in the morning and once in the evening, for up to 12 weeks.~The inhalations were scheduled to be taken approximately 12 hours (but not less than 6 hours) apart, eg, at 08:00 and 20:00 each day. Nebulization time per inhalation dose was approximately 8 to 13 minutes for the 0- and 10-mg doses.~Standard of care included prophylaxis against common opportunistic infections, immunosuppression, and any other chronic medication
- L-CsA 5 mg plus Standard of Care (Type: EXPERIMENTAL): Liposomal Cyclosporine A 5 mg (5 mg/1.25 mL) bid, once in the morning and once in the evening, for up to 12 weeks. The inhalations were scheduled to be taken approximately 12 hours (but not less than 6 hours) apart, eg, at 08:00 and 20:00 each day. Nebulization time per inhalation dose was approximately 5 to 10 minutes for the 5-mg dose.~Standard of care included prophylaxis against common opportunistic infections, immunosuppression, and any other chronic medication
- Liposomal Placebo plus Standard of Care (Type: PLACEBO_COMPARATOR): Liposomal Placebo 2.5 mL (0 mg L-CsA/2.5 mL) bid, once in the morning and once in the evening, for up to 12 weeks.~The inhalations were scheduled to be taken approximately 12 hours (but not less than 6 hours) apart, eg, at 08:00 and 20:00 each day. Nebulization time per inhalation dose was approximately 8 to 13 minutes for the 0- and 10-mg doses. Standard of care included prophylaxis against common opportunistic infections, immunosuppression, and any other chronic medication

Based on this trial design, predict the completion outcome and termination type (if applicable).